**Question:** The failure rate of TODAY is lowest in:

A.
B.
C.
D.

**Correct Answer:** D.

**Core Concept:** TODAY stands for Ticagrelor, Oral Dual Antiplatelet Therapy, which is a widely used antiplatelet regimen in patients undergoing percutaneous coronary intervention (PCI). It involves the combination of a P2Y12 inhibitor (e.g., ticagrelor) and a PPI (e.g., omeprazole) to reduce the risk of major adverse cardiovascular events after PCI.

**Why the Correct Answer is Right:** In this scenario, the correct answer (D) refers to the combination therapy of ticagrelor (a P2Y12 inhibitor) and omeprazole (a PPI). The combination of these two medications significantly reduces the risk of major adverse cardiovascular events (MACE) in patients undergoing PCI.

Omeprazole is a PPI that inhibits gastric acid secretion, while ticagrelor is a selective and reversible P2Y12 inhibitor that blocks adenosine diphosphate (ADP) receptors on platelets, thereby preventing platelet aggregation and reducing thrombosis risk. The combination of these two drugs synergistically lowers the risk of MACE, making D the correct answer.

**Why Each Wrong Option is Incorrect:**

A: This option refers to the use of aspirin, a single antiplatelet agent, which is not as effective as the combination of ticagrelor and omeprazole in reducing MACE after PCI.
B: While dual antiplatelet therapy (DAPT) is essential after PCI, it does not specify the correct combination of ticagrelor and omeprazole.
C: This option mentions clopidogrel, another P2Y12 inhibitor, but omeprazole is not involved in reducing the risk of MACE in this context.

**Clinical Pearl:** The combination of ticagrelor and omeprazole (option D) is crucial in reducing the risk of MACE in patients undergoing PCI. This combination helps to achieve optimal platelet inhibition and gastric protection, leading to a lower risk of bleeding complications and thrombotic events.

In clinical practice, the use of DAPT (dual antiplatelet therapy) with aspirin and clopidogrel is commonly prescribed after PCI. However, the combination of ticagrelor (a P2Y12 inhibitor) and omeprazole (a PPI) is the most effective regimen for reducing the risk of MACE (major adverse cardiovascular events) in patients undergoing PCI. This combination ensures both optimal platelet inhibition and gastric protection, minimizing bleeding complications and thrombotic events.

**Why Each Wrong Option is Incorrect:**

A: Aspirin is a P2Y12 inhibitor but omeprazole is not involved in reducing the risk of MACE in this context.
B: While DAPT (dual antiplatelet therapy) is essential after PCI, omeprazole is not the correct PPI to be administered along with ticagrelor to reduce M